Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Tepoditamab (MCLA-117) is a bispecific monoclonal antibody designed to target CLEC12A on myeloid cells and CD3 on cytotoxic T cells. CLEC12A serves as a myeloid differentiation antigen. The compound effectively eliminates AML leukemia progenitor and stem cells by inducing T cell-mediated proliferative lysis, making it a valuable asset in acute myeloid leukemia (AML) research [1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | Inquiry | Inquiry |
Description | Tepoditamab (MCLA-117) is a bispecific monoclonal antibody designed to target CLEC12A on myeloid cells and CD3 on cytotoxic T cells. CLEC12A serves as a myeloid differentiation antigen. The compound effectively eliminates AML leukemia progenitor and stem cells by inducing T cell-mediated proliferative lysis, making it a valuable asset in acute myeloid leukemia (AML) research [1]. |
Molecular Weight | N/A |
CAS No. | 2044679-53-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Tepoditamab 2044679-53-8 inhibitor inhibit